ECCO 2017 | Survival improvements in melanoma
Paolo Ascierto, MD, of the National Tumor Institute Fondazione G. Pascale, Naples, Italy, discusses survival in melanoma patients at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Survival for melanoma patients over the last 5 years has improved, with the median overall survival being 30 months. There is currently no data for PD1 in combination, however, this is expected to show promising results. Clinical trials are necessary to determine the best course of actions for patients, and this can differ depending on certain factors, such as age, LDH level, and the presence of brain metastases. Current treatment for melanoma is targeted therapy and immunotherapy, however, with more data, more effective treatments can be used, and there will be further improvement in long term survival.
Get great new content delivered to your inboxSign up